Proteomic analysis of non‐muscle invasive and muscle invasive bladder cancer highlights distinct subgroups with metabolic, matrisomal, and immune hallmarks and emphasizes importance of the stromal compartment
The Journal of Pathology · 2025
DOI: 10.1002/path.6367 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Pathology, 2025. Verfasst von Thien-Ly Julia Dinh und 30 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Surgical Pathology, Faculty of Medicine, Medical Center-University of Freiburg, University of Freiburg, Freiburg, Germany. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Proteomics, Tumor Microenvironment, Neoplasm Invasiveness. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: ERA TransCan program, invest BW program, EPIC-XS Consortium.
Abstract (Originalsprache)
We present the proteomic profiling of 79 bladder cancers, including treatment‐naïve non‐muscle‐invasive bladder cancer (NMIBC, n = 17), muscle‐invasive bladder cancer (MIBC, n = 51), and neoadjuvant‐treated MIBC ( n = 11). Proteins were extracted from formalin‐fixed, paraffin‐embedded samples and analyzed using data‐independent acquisition, yielding >8,000 quantified proteins. MIBC, compared to NMIBC, shows an extracellular matrix (ECM) and immune response signature as well as alteration of the metabolic proteome together with concomitant depletion of proteins involved in cell–cell adhesion and lipid metabolism. Neoadjuvant treatment did not consistently impact the proteome of the residual tumor mass. NMIBC presents two proteomic subgroups that correlate with histological grade and feature signatures of cell adhesion or lipid/DNA metabolism. Treatment‐naïve MIBC presents three proteomic subgroups with resemblance to the basal‐squamous, stroma‐rich, or luminal subtypes and signatures of metabolism, immune functionality, or ECM. The metabolic subgroup presents an immune‐depleted microenvironment, whereas the ECM and immune subgroups are enriched for markers of M2‐like tumor‐associated macrophages and dendritic cells. Markers for natural killer cells are exclusive for the ECM subgroup, and markers for cytotoxic T cells are a hallmark of the immune subgroup. Endogenous proteolysis is increased in MIBC alongside upregulation of matrix metalloproteases, including MMP‐14. Genomic panel sequencing yielded the prototypical profile of prevalent FGRF3 alterations in NMIBC and TP53 alterations in MIBC. Tumor–stroma interactions of MIBC were investigated by proteomic analysis of patient‐derived xenografts, highlighting specific tumor and stroma contributions to the matrisome and tumor‐induced stromal proteome phenotypes. © 2024 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Surgical Pathology, Faculty of Medicine, Medical Center-University of Freiburg, University of Freiburg, Freiburg, Germany.
- Faculty of Biology, University of Freiburg, Freiburg, Germany.
- Institute of Pharmaceutical Sciences, University of Freiburg, Freiburg, Germany.
- Department of Pharmaceutical Chemistry and Bioanalytics, Institute of Pharmacy, Martin Luther University Halle-Wittenberg, Halle, Germany.
- Bellvitge Institute for Biomedical Research (IDIBELL), L'Hospitalet del Llobregat, Barcelona, Spain.
- Spemann Graduate School of Biology and Medicine, Freiburg, Germany.
ORCID-Profile: Manuel Rogg, Miguel Cosenza-Contreras, Patrick Bernhard
Förderung
- ERA TransCan program
- invest BW program
- EPIC-XS Consortium
- Bundesministerium fuer Bildung und Forschung
- Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement de la Generalitat de Catalunya
- Spanish Ministry of Science
- ERA PerMed
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Dinh, T. J., Rogg, M., Cosenza-Contreras, M., Li, M., Zirngibl, M., Pinter, N., Kurowski, K., Hause, F., Pauli, L., Imberg, F., Huynh, A., Schmid, M., Glavinsky, I., Braun, L., Van Wymersch, C., Bergmann, L., Ungefug, X., Kunz, M., Werner, T., …, & Schilling, O. (2025). Proteomic analysis of non‐muscle invasive and muscle invasive bladder cancer highlights distinct subgroups with metabolic, matrisomal, and immune hallmarks and emphasizes importance of the stromal compartment. The Journal of Pathology. https://doi.org/10.1002/path.6367
Vancouver
Dinh TJ, Rogg M, Cosenza-Contreras M, Li M, Zirngibl M, Pinter N, et al. Proteomic analysis of non‐muscle invasive and muscle invasive bladder cancer highlights distinct subgroups with metabolic, matrisomal, and immune hallmarks and emphasizes importance of the stromal compartment. The Journal of Pathology. 2025. doi:10.1002/path.6367
BibTeX
@article{Dinh2025,
author = {Dinh, Thien-Ly Julia and Rogg, Manuel and Cosenza-Contreras, Miguel and Li, Mujia and Zirngibl, Max and Pinter, Niko and Kurowski, Konrad and Hause, Frank and Pauli, Lena and Imberg, Fiona and Huynh, Alana and Schmid, Marlene and Glavinsky, Ievgen and Braun, Luisa and Van Wymersch, Clara and Bergmann, Luise and Ungefug, Xenia and Kunz, Marion and Werner, Tilman and Bernhard, Patrick and Espadas, Guadalupe and Brombacher, Eva and Schueler, Julia and Sabido, Eduard and Kreutz, Clemens and Gratzke, Christian and Werner, Martin and Grabbert, Markus and Bronsert, Peter and Schell, Christoph and Schilling, Oliver},
title = {Proteomic analysis of non‐muscle invasive and muscle invasive bladder cancer highlights distinct subgroups with metabolic, matrisomal, and immune hallmarks and emphasizes importance of the stromal compartment},
journal = {The Journal of Pathology},
year = {2025},
doi = {10.1002/path.6367}
}
EUVIMED